Infectious disease treatment continues to face persistent challenges as existing therapies struggle to address evolving pathogens and inflammatory complications. Celestial Therapeutics focuses on developing new therapeutic platforms designed to expand treatment options for viral infections and inflammatory diseases. The company's scientific strategy centers on three technology platforms that target different aspects of infectious disease treatment, including antiviral therapies, mRNA-based vaccines and anti-inflammatory drugs. "Our lead antiviral drug, CT-02, has a unique mechanism of action that makes it effective against a number of enveloped and non enveloped viruses and strains," says Ajay Gupta, CEO, president and chairman..

What data management challenges exist across modern drug discovery workflows and research environments? Drug discovery operates across laboratories, clinical trials, and computational models, generating an immense volume of data on everything from genetic information to chemical compounds, clinical outcomes, and preclinical results. The challenge is not just gathering data but structuring, analyzing, and storing it in a way that ensures accessibility and interpretability for researchers, developers, and decision-makers. While managing this data is intricate and demanding, Collaborative Drug Discovery’s (CDD) solution simplifies the process, offering a streamlined and efficient approach to overcoming these complexities. A Silicon Valley-based company, CDD has created CDD Vault, a web-based solution designed to streamline chemical and biological data management across the entire drug discovery process. An essential part of the platform is CDD Vault’s Electronic Laboratory Notebook (ELN), which enables scientists to capture experimental procedures, observations, and results in the same secure environment where chemical and biological data are managed and shared. The platform enables drug discovery teams to manage and analyze data from multiple disciplines within a single, secure, easy-to-use system and has garnered the trust of researchers, scientists, and companies around the globe. Dr. Barry A. Bunin, CEO and President, leads the company with a strong vision rooted in his deep understanding of the challenges faced by researchers in the field. He notes, “Our platform continues to empower researchers to make more informed, data-driven decisions in drug discovery.” Pioneering a New Era in Scientific Data Management How did CDD Vault evolve as a web-first solution for scientific data management? When Dr. Bunin founded CDD, the vision was clear: to create a solution that would streamline data management in drug discovery by simplifying complexity. The goal was to enable researchers to handle large volumes of chemical and biological data with ease while ensuring secure collaboration across teams and organizations. From the very beginning, CDD Vault was conceived as a web-first solution, long before cloud computing became mainstream. “One of the key differentiators for CDD Vault is that it is not just about managing data; it is about making the data work for you. The platform simplifies complexity so researchers can focus on discovery rather than getting bogged down in the intricacies of data management,” says Dr. Bunin. “Our tagline, ‘Complexity Simplified,’ reflects this philosophy because we have built a system that does all the heavy lifting so you do not have to.” CDD Vault was one of the first hosted systems to come to market, even before cloud computing platforms such as AWS gained widespread adoption. By offering a cloud-based solution, CDD Vault has enabled research teams to collaborate across geographies with high levels of security and efficiency. With servers in both North America and Europe, 99.9 percent uptime, and a flawless security track record, the platform ensures that sensitive data remains protected while providing researchers with the tools they need to accelerate their work. Simplifying Collaboration Across Teams and Companies How does CDD Vault enable secure collaboration across teams, partners, and organizations? One of the core principles Dr. Bunin emphasized during the development of CDD Vault was collaboration. Drug discovery is rarely a solo endeavor; it involves teams of scientists, researchers, and clinicians from different disciplines working together to solve complex problems. Whether it is a chemist working alongside a biologist or a biotech firm collaborating with a large pharmaceutical company, seamless communication and data sharing are essential. “One of the things we hear from customers all the time is that CDD Vault makes collaboration much easier. Whether you are working with different teams within the same company or with external partners such as CROs, large pharmaceutical companies, or academic institutions, the platform ensures data is shared securely and that all stakeholders remain aligned,” Dr. Bunin explains. The ability to collaborate securely across companies and disciplines has made CDD Vault valuable to organizations ranging from startups to large pharmaceutical companies. This capability also delivers meaningful economic advantages. Rather than placing dedicated personnel on-site for weeks or months, companies can onboard new teams or external partners quickly through online meetings and training sessions, saving both time and money. Security remains a top priority, and CDD Vault was designed with the principle of secure collaboration in mind. The platform’s architecture enables precise data partitioning, ensuring that sensitive data is accessible only to authorized users, whether inside or outside the organization. This level of security has been critical in building trust, particularly in an industry where confidentiality and regulatory compliance are paramount. .

How does scientific ownership support reliable process development from laboratory to commercial manufacturing? Complex therapies move forward when chemistry is mastered at scale. For organizations accountable for delivering safe, scalable, and compliant therapies, progress depends on deep process understanding, consistent quality controls, and scientist-led teams who stay connected as programs grow. For chronic disease and oncology programs, a streamlined workflow from development to manufacturing ensures timelines stay on track and risks remain under control. Realizing that principle in practice is Tianyu Pharm, a contract development and manufacturing organization (CDMO) that produces key intermediates and APIs while controlling every stage, from raw starting materials to production. Building over three decades of trust with global pharmaceutical and biotechnology partners, the company empowers its scientist-led teams with structured project management to innovate, optimize processes, and deliver reliable solutions. “Our scientist-led approach empowers specialized teams, drives process development, and delivers consistent, high-quality results for our clients,” says Robert L. Moore, Ph.D., Senior Director of Business Development. At Tianyu, chemists do not hand off their work when a process leaves the lab. They develop the reactions and guide the process through scale-up and commercial manufacturing, applying their insights at every step. Additionally, the engineering team is involved at every step of process development, ensuring that the physical infrastructure aligns with the chemistry to further ensure quality and cost-effectiveness of manufacturing at scale. With a stable workforce of more than 4,000 employees and over 200 PhDs and Master’s leading process development and scale-up, the company integrates scientific ownership into every stage of production. It maintains stable production teams across long-term development programs, with approximately 95 percent annual employee retention..

Why is recurrence prediction challenging in early breast cancer cases? A diagnosis of early breast cancer sets off a cascade of decisions: surgery, radiation, endocrine therapy, and years of follow-up. Yet one question often remains harder to answer than any other: Will this cancer actually come back? Modern medicine is highly effective at detecting early breast lesions. What it has struggled with is distinguishing which of those lesions are biologically aggressive and which are unlikely to recur. Without precise prognostic tools, treatment decisions are frequently guided by population-level risk models rather than by the individual biology of a patient’s tumor. Predictoma is built to understand which cancer truly matters. The company applies AI-driven spatial image analysis to evaluate recurrence-associated cell populations within tumor tissue. Rather than identifying cancer alone, the platform analyzes biomarker distribution patterns to determine whether a tumor is likely to recur or remain indolent. “Designed for seamless integration into existing clinical laboratories, our software delivers patient-specific prognoses with greater than 95 percent accuracy,” says Howard Petty, CEO. By distinguishing between aggressive and non-aggressive disease—often years before recurrence would otherwise become clinically evident—the platform supports more informed surgical, therapeutic, and surveillance decisions. Existing CPT pathways enable reimbursement, and the system has demonstrated no racial bias in prognostic performance. Predictoma is currently progressing through FDA review as it prepares for clinical deployment..